BackTaysha Gene Therapies Overview
Taysha Gene Therapies Inc

Taysha Gene Therapies Target Price

Where could TSHA trade next? Consensus target price: $14.

Get informed when a big investor buys or sells

+ Follow

Share Price

$6.2

Average Target Price

$14.00125.8% upside

3 analysts in the last 4 months

High: $15 | Low: $13

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-21Goldman Sachs$13109.7% upsideOpen
2026-06-30Robert W. Baird$15141.9% upsideOpen
2026-06-23Pivotal ResearchKeith Tapper$14125.8% upsideOpen
2026-01-06Raymond JamesChris Raymond$13109.7% upsideOpen
2026-01-05Wells FargoZachary Fadem$1177.4% upsideOpen
2025-12-04Goldman Sachs$1177.4% upsideOpen
2025-12-04UBS$1177.4% upsideOpen
2025-11-14Cantor FitzgeraldKristen Kluska$13109.7% upsideOpen
2025-11-05JMP Securities$829% upsideOpen
2025-10-02Robert W. BairdJack Allen$1293.5% upsideOpen
2025-10-02NeedhamGil Blum$1061.3% upsideOpen
2024-08-14BMO CapitalKeith Tapper$519.4% downsideOpen
2024-07-01Piper SandlerChristopher Raymond$712.9% upsideOpen
2024-05-14JefferiesEun Yang$829% upsideOpen
2024-04-09Raymond JamesChristopher Raymond$945.2% upsideOpen
2023-02-01Jefferies$1.575.8% downsideOpen
2021-10-19Morgan StanleyMatthew Harrison$39529% upsideOpen
2021-05-19Cantor FitzgeraldKristen Kluska$44609.7% upsideOpen

Taysha Gene Therapies (TSHA) FAQ

Taysha Gene Therapies (TSHA) currently reports a target price of $14. Use the charts on this page to explore Taysha Gene Therapies's target price history and peer comparisons.

Analysts' average 12-month price target for Taysha Gene Therapies is $14, about 125.8% upside from the current share price of $6.2. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $14, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Taysha Gene Therapies, and consider following TSHA for alerts when major investors trade the stock.

Taysha Gene Therapies is classified in the Healthcare sector. On target price, it currently shows $14. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TSHA with unrelated industries.